Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low Level of Genomic Alteration to Predict Exceptional and Unexpected Response to Targeted Therapies in Patients With Solid Tumors

NCT02701907 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02701907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02701907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low Level of Genomic Alteration to Predict Exceptional and Unexpected Response to Targeted Therapies in Patients With Solid Tumors
Lead sponsor
UNICANCER
Phase
Not applicable
Overall status
Completed
Start date
December 31, 2016
Completion date
April 17, 2022
Enrollment
182 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancers